Questionnaires used in research to assess behavior, communication, and quality of life in people with Lennox-Gastaut syndrome (LGS) may not always capture the concerns that matter most to patients and their families, a study found. In focus groups involving caregivers, clinicians, and advocates, participants identified several areas they felt…
News
Fintepla (fenfluramine) can rapidly reduce seizure frequency in people with Lennox–Gastaut syndrome (LGS), with the greatest benefits typically appearing after a few months of treatment and common side effects often becoming less noticeable over time, according to a post hoc analysis of Phase 3 clinical data. “Patients, parents,…
Children with Lennox-Gastaut syndrome (LGS) experience substantial sleep disruptions, which caregivers can track at home with an electroencephalogram (EEG) headband, a study found. The HEADFIRST study showed that the Waveband device, which uses four sensors placed over the front and back of the head to record the brain’s…
Two nerve-stimulating devices, vagus nerve stimulation (VNS) and deep brain stimulation (DBS), were associated with similar reductions in seizure frequency over two years in people with Lennox-Gastaut syndrome (LGS), according to a Mayo Clinic study. At two years, however, combined DBS and ongoing VNS was associated with greater seizure…
The initial results from a large, late-stage clinical trial testing an oral seizure treatment for people with Lennox-Gastaut syndrome (LGS) and other epileptic conditions are expected by the end of this year or early next year. That’s according to new updates from Lundbeck, a pharmaceutical company specializing in treating…
Carisbamate, an experimental oral therapy for the treatment of seizures in people with Lennox-Gastaut syndrome (LGS), was generally safe and well-tolerated in children, adolescents, and adults with the disease, according to data from a Phase 1 safety study. The antiseizure medication also showed consistent pharmacokinetics, or how the…
A new mouse model of Lennox-Gastaut syndrome (LGS) accurately reproduced key features of the disease and responded to approved and investigational therapies, providing the first pharmacological validation of the model, a new study reports. “These promising results suggest the mouse model could be a valuable tool for drug discovery…
A girl with difficult-to-treat CDKL5 deficiency disorder (CDD), whose epilepsy later developed into Lennox–Gastaut syndrome (LGS), became seizure-free for more than 11 months after treatment with low-dose Fintepla (fenfluramine), suggesting this medication may be a potential option for similarly hard-to-treat seizures, according to a report from Japan. After starting…
The Lennox-Gastaut Syndrome (LGS) Foundation has launched a collaborative research accelerator to unite experts, dismantle research roadblocks, and speed up the development of new treatments for LGS and related developmental and epileptic encephalopathies (DEEs). The newly formed LGS and Associated DEE Research Accelerator brings together pharmaceutical companies, academic…
A team of experts in Italy has proposed a framework for the routine monitoring of nonseizure symptoms in people with Lennox-Gastaut syndrome (LGS) throughout their lives. While the framework is a good place to start, the researchers noted a need for better assessment tools to adequately capture these symptoms and…
Recent Posts
- Life took an unexpected turn after my son’s Lennox-Gastaut diagnosis
- Doctor checklist aims to facilitate earlier LGS diagnosis
- Guest Voice: Anticipating LGS challenges as my son is growing up
- EEG requirements may not capture full LGS spectrum
- Study says LGS questionnaire design may not capture family needs